Insys Therapeutics, Inc. Accretion Expense
Insys Therapeutics, Inc. reported Accretion Expense of -$2.11 million for the 12-month period ending 2012-12-31, per its 10-K filed 2014-03-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2014-03-05
- Insys Therapeutics, Inc. accretion expense for the quarter ending 2012-12-31 was -$2.32M.
- Insys Therapeutics, Inc. accretion expense for the quarter ending 2012-09-30 was $70.00K.
- Insys Therapeutics, Inc. accretion expense for the quarter ending 2012-06-30 was $70.00K.
- Insys Therapeutics, Inc. accretion expense for the quarter ending 2012-03-31 was $70.00K.
- Insys Therapeutics, Inc. accretion expense for fiscal 2012 was -$2.11M.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-05 | -$2.25M derived: sum of 2 quarters · filed 2014-03-05 | -$2.18M derived: sum of 3 quarters · filed 2014-03-05 | -$2.11M 10-K · filed 2014-03-05 |
| 2012-09-30 | $70.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $140.00K derived: sum of 2 quarters · filed 2013-11-12 | $210.00K 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $70.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | $140.00K 10-Q · filed 2013-08-13 | ||
| 2012-03-31 | $70.00K 10-Q · filed 2013-06-05 |